News and Media

Hospitals will receive nearly BGN 15.2 million more by the end of the year, informed reporters the member of the Supervisory Board of the NHIF Dr. Vanyo Sharkov last Wednesday. He explained that the Supervisory Board at a meeting has made a decision the university hospitals budgets to be increased by 2%, while the budgets of all others who provide emergency services – by 1%. A day later it became clear that in addition to the initially announced 146 hospitals, which will receive more funding, over 70 more hospitals have submitted applications. The money will be deducted from the reserve of the NHIF.

“It all is based on the decision and what we proposed at the previous meeting – to increase the budgets for providing emergency medical care. The operational management of the NHIF provided the lists and the distribution was carried out accordingly. What the operational leadership offered, we have adopted,” said the member of the Supervisory Board.

Dr. Sharkov said that “Pirogov Hospital” will receive most additional resources – about BGN 1 million. “University hospitals and hospitals with emergency consultation wards include: ‘Aleksandrovska Hospital’, ’Pirogov Hospital’, The Military Medical Academy, The Medical Institute of the Interior ‘St. George’, and ‘St. Marina’, “ he replied to the question which hospitals come after “Pirogov Hospital”.

The Director of the NHIF Dr. Glinka Komitov noted that the operational management of the Fund will offer additional funding only to hospitals with motivated demands. According to his forecast, in order to satisfy the demands of these hospitals, about BGN 50 million would be needed. Realistically, however, the allocated amount would be much less, said the Director of the NHIF.
The Supervisory Board of the institution is expected to examine these proposals on May 25^th.

The Health Minister takes on the medicine procurement in hospitals, announced the Council of Ministers in its Draft Decree. It was published on the website of the Ministry of Health for public comment.

In his new activity, the Minister will be assisted by a new unit in the Department, which will be created for the occasion – the “Central Unit for Negotiation and Administration.”

As a central authority, responsible for procurement in the “Healthcare” sector, the Minister will plan, prepare and carry out medicine procurement procedures. He will also be concluding framework agreements on behalf of hospitals.

Based on the concluded framework agreements, hospitals will determine the contractor using electronic auction and will conclude individual agreements, envisages the document.

The Minister will have the power to supervise the implementation of the framework agreements in relation to their compliance with their conditions – prices, quantities, deadlines and more.

The project also includes the possibility, if necessary, the Health Minister to conduct procedures to conclude the framework agreement on behalf of hospitals, through electronic auction.

One year after the Decree comes into force, the Health Minister has to provide conditions for conducting an auction through an integrated information system – an online platform for e-commerce needs of hospitals – indicates the text.

Until the conclusion of the framework agreement under this Decree, the medical institutions will provide their medications under the previous order, and the existing framework agreements and contracts with the same subject, concluded by hospitals’ management, will retain their validity for the period for which they have been concluded, except if terminated before the expiry of their term, it becomes clear from the draft document.

The change will result in time savings, administrative and financial resources for the hospitals and will reduce drug prices, are the motives of the Health Ministry. Furthermore, the reorganization will enable a faster and better response to the needs of hospitals, the presence of stable contracts and easing the system responsible for appeal procedures, according to the Department. According to them, the introduction of e-procurement will also facilitate the participation of all wholesalers, who are listed in the register for holding an authorization for medicines wholesale, and will increase the competition and improve the contracting sector conditions.

The extended use of electronic means and resources and the integration of the platform with the existing electronic records will contribute to the full publicity and transparency to effectively confront and prevent corruption in the sector, is said in a statement.

People between 18 and 49 years of age with isolated systolic hypertension (ISH) have increased risk of death from cardiovascular causes or ischemic heart disease (IHD) according to the results of a study published in the Journal of the American College of Cardiology.

The authors used a database of patients from 1967 to 2003 and evaluated the risk of developing cardiovascular disease (CVD) in the presence of ISH, defined as systolic blood pressure (SBP)> / = 140 mmHg and diastolic blood pressure (DBP) <90 mmHg in men and women under the age of 50.

27,081 participants were classified into five categoriesm, based on the values of BP: optimal BP (SBP <130 DBP <85 mmHg); high normal BP (130-139 / 85-89 mmHg); ISH (SBP> / = 140 mmHg and DBP <90 mmHg); isolated diastolic hypertension (IDH; SBP <140 and DBP> / = 90 mmHg) and systolic – diastolic hypertension (SDH; SBP> / = 140 mmHg and DBP> / = 90 mmHg).

According to this distribution, 53% of the women had optimal baseline BP and 13% – ISH, while among men – around 25% of the participants fell into each category: optimal blood pressure, high normal BP and ISH. Patients with known coronary artery disease and those taking antihypertensive medications were excluded.

The results showed that after 31 years of follow up the participants with baseline ISH were at increased risk for CVD and CHD mortality as compared to those who had optimal or normal blood pressure or high IDH. The relationship described was more pronounced in women. The risk in patients with ISH, however, was lower than that in patients with SDH.

Up to that point ISH at a young age had not attracted particular attention as a risk factor, but the data from this study showed that ISH was associated with an increased risk of CVD and mortality.

Since the frequency of hypertension, obesity and lipid profile disorders among young people have been increasing substantially, early intervention in the course of the disease and the promotion of a healthy lifestyle could significantly influence the future incidence of adverse cardiovascular events.

According to the Guidelines for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension (ESC / ESH), the preferred antihypertensive drugs for adults with ISH are calcium channel blockers (CCBs) and diuretics with class indication ΙA.

Some meta-analyzes suggest that CCBs may be more effective than other antihypertensive classes for stroke prevention (perhaps precisely because of the favorable influence of SBP, whose values are closely associated with stroke risk).
In addition, this class of drugs has been shown to lower the central aortic pressure, improving the endothelial function, and it also has antiatherosclerotic effects.

Ireland, the United Kingdom and Albania are the first three countries in Europe in child obesity. Bulgaria is fifth, according to a study published at a Congress on the problem in Prague. The study has been conducted with the participation of the World Health Organization (WHO) based on data for children aged up to 5 years in 32 countries of the Old Continent.

In Ireland, 27.5% of the children under the age of 5 are fat or obese, while in the UK they are 23.1%. Albania follows with 22%, and Georgia – with 20%.

In Bulgaria 19.8% of the children aged up to 5 years are obese. Spain follows with 18.4%. At the opposite pole are the Czech Republic – with 5.5 percent, Belgium – with 7% and 8% – in Sweden. Italy and France are in the middle of the table, respectively by having 10.2% and 11.4%.

Another study, presented at the colloquium in the Czech capital, concluded it was more likely that obese children leave school early compared to the ones with normal weight. 56% of overweight children under the age of 12 regularly attend school. This applies to 76 percent of their other peers.
According to the WHO estimates presented in Prague, by 2030 Europe will be facing a large scale obesity epidemic among its working-age population.

One of the most prominent Italian neurologists and acknowledged European experts in the field of Parkinson’s disease Prof. Angelo Antonini was an official guest speaker at the 14th National Congress of Neurology, held over the weekend in the resort “Golden Sands”, announced the organizers of the forum. Prof. Antonini is Director of the Department of Parkinsonism at the Institute of Neurology, “San Camillo” in Venice. The topic of his lecture focused on the possibilities for modern treatment of the late stages of Parkinson’s disease. The neurologist presented his clinical experience with the leading contemporary therapy that is currently applied for this indication – treatment with levodopa / carbidopa intestinal gel.

The method has been among the preferred ones by professionals in the recent years, and very good therapy results and usability have been reported. This method is also known in Bulgaria and has been used for several years in a few university clinics. The treatment is entirely reimbursed by the NHIF and so far our neurologists have successful experience with 40 patients. Prof. Antonini arrived in Bulgaria from Romania, where he was a speaker at the Romanian Neurological Congress and participated in a discussion with Romanian neurologists, who were presented the treatment results of using this method and the follow up results of 200 Romanian patients.

Tchaikapharma High Quality Medicines AD has been offering on the Bulgarian market a drug designed to treat the symptoms of Parkinson’s disease since 2009. Sinepar is a medicine which combines the aromatic amino acid carbidopa monohydrate (a decarboxylase inhibitor) with levodopa (a metabolic precursor of dopamine) in an extended release tablet formulation of the active substance.